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ABSTRACT 
Background 
The associations between pregnancy hypertensive disorders and common cardiovascular 
disorders have not been investigated at scale in a contemporaneous population. We aimed 
to investigate the association between preeclampsia, hypertensive disorders of pregnancy 
and subsequent diagnosis of 12 different cardiovascular disorders.  
  
Methods 
We used linked electronic health records from 1997 to 2016 to recreate a UK population-
based cohort of 1.3 million women, mean age at delivery 28 years, with nearly 1.9 million 
completed pregnancies. We used multivariable Cox models to determine the associations 
between hypertensive disorders of pregnancy (HDP), and preeclampsia alone (term and 
preterm), with 12 cardiovascular disorders in addition to chronic hypertension. We 
estimated the cumulative incidence of a composite endpoint of any cardiovascular disorder 
according to preeclampsia exposure.  
 
Results 
During the 20 year study period, 18,624 incident cardiovascular disorders were observed, 
65% of which had occurred in women under 40 years. Compared to women without 
hypertension in pregnancy, women who had one or more pregnancies affected by 
preeclampsia had a hazard ratio (HR) of 1.9 (95%CI 1.53-2.35) for any stroke, 1.67 (1.54-
1.81) for cardiac atherosclerotic events, 1.82 (1.34-2.46) for peripheral events, 2.13 (1.64-
2.76) for heart failure, 1.73 (1.38-2.16) for atrial fibrillation, 2.12 (1.49-2.99) for 
cardiovascular deaths and 4.47 (4.32-4.62) for chronic hypertension. Differences in 
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cumulative incidence curves, according to preeclampsia status, were apparent within one 
year of the first index pregnancy. Similar patterns of association were observed for HDP, 
whilst preterm preeclampsia conferred slightly further elevated risks.   
 
Conclusions 
Hypertensive disorders of pregnancy, including preeclampsia, have a similar pattern of 
increased risk across all 12 cardiovascular disorders and chronic hypertension, and the 
impact was evident soon after pregnancy. HDP should be considered as a natural screening 
tool for cardiovascular events, enabling cardiovascular risk prevention through national 
initiatives.   
 
Keywords 
Preeclampsia, hypertensive disorders of pregnancy, pregnancy, cardiovascular disease, 
hypertension.  
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CALIBER; Cardiovascular research using Linked Bespoke studies and Electronic health 
Records  
HDP; hypertensive disorders of pregnancy  
EHR; electronic health records  
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ONS; Office for National Statistics 
NOS; not otherwise specified 
HR; Hazard ratios  
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CLINICAL PERSPECTIVE 
What is new? 
 Compared to women without preeclampsia, women who had one or more 
pregnancies affected by preeclampsia had elevated hazard ratios for any stroke, for 
cardiac atherosclerotic events, for peripheral events, heart failure, atrial fibrillation 
and cardiovascular deaths. 
 Differences in cumulative incidence curves, according to preeclampsia status, were 
apparent within one year of the first index pregnancy.  
 Simil r patterns of association were observed for hypertensive disorders of 
pregnancy, whilst preterm preeclampsia conferred further elevated risks.   
What are clinical implications? 
 Women with any hypertensive disorders of pregnancy, in particular preterm 
preeclampsia, are at increased risk of all cardiovascular disorders.  
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 The age for cardiovascular screening may need to be reduced for women with a 
history of hypertensive disorders of pregnancy.  
 Hypertensive disorders of pregnancy should be considered as a natural screening 
tool for premature cardiovascular events, enabling cardiovascular risk prevention 
through national initiatives.   
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INTRODUCTION 
Preeclampsia affects 2-8% of pregnancies worldwide manifesting as hypertension and 
proteinuria in the second half of pregnancy.1 Globally, preeclampsia is responsible for 
around 14% of maternal deaths2 and is a major cause of perinatal morbidity and mortality.  
 
Two decades of research have documented an association between preeclampsia, and 
major cardiovascular disorders in later life.3-8 However, there are several limitations with the 
current evidence that prevent its translation into clinical care. Firstly, most research to date 
has focused on the use of composite end-points such as ischemic heart disease and 
cerebrovascular disorders, which include a heterogenous group of disorders with diverse 
aetiologies and clinical management. Secondly, over the past two decades the pattern of 
initial presentation of cardiovascular disorders has changed substantially in high-income 
countries such as the UK, with most of the events being neither myocardial infarction nor 
ischemic stroke.9 Thirdly, only a minority of studies4, 10, 11 have been able to adjust for post-
pregnancy cardiovascular risk factors, such as hypertension, limiting their ability to examine 
potential mediating factors underlying this association.  
 
To resolve these uncertainties, we used linked electronic health records to create a large-
scale, contemporaneous pregnancy cohort of around 1.3 million participants over a twenty 
year period. We used this population-based cohort to investigate the association of 
preeclampsia, preterm preeclampsia, and other hypertensive disorders of pregnancy (HDP) 
with the 12 most common initial diagnoses of cardiovascular disorders in the UK, in addition 
to chronic hypertension. We also carried out exploratory analyses to investigate the extent 
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to which the preeclampsia/cardiovascular disease association was explained by post-
pregnancy hypertension. 
 Dis
cla
im
er:
 Th
e m
an
us
cri
pt 
an
d i
ts 
co
nte
nts
 ar
e
co
nfi
de
nti
al,
 in
ten
de
d f
or 
jou
rna
l re
vie
w p
urp
ose
s
 
 
 
 
 
 
 
 
 
 
 
on
ly,
 an
d n
ot 
to 
be
 fu
rth
er 
dis
clo
se
d.
3 
 
METHODS 
Study design and data sources 
We recreated a longitudinal population-based cohort study using linked routine electronic 
health records (EHR). Women were selected from the Cardiovascular research using Linked 
Bespoke studies and Electronic health Records (CALIBER)12 resource 
(https://www.caliberresearch.org/portal) which contains verified and reproducible health 
phenotypes for hundreds of variables, including the 12 cardiovascular phenotypes 
investigated as outcomes in this analysis.12 CALIBER and its associated phenotype algorithms 
combine longitudinal data from the Clinical Practice Research Datalink (CPRD),13 Hospital 
Episodes Statistics (HES),14 and Office for National Statistics (ONS) cause-specific mortality 
records.15 See supplementary methods for further details. The analytic methods are 
available to other researchers for purposes of reproducing the results or replicating the 
procedure (in the online-only Data Supplement). We are not authorized to share the data 
 
Participants  
Participants were eligible for inclusion in the study if they were female, registered at any 
General Practitioner participating in the CPRD with ‘up-to-standard’ (UTS) data, and they 
had consented to linkage with HES and ONS.  
 
Preeclampsia, the exposure of interest, is a syndrome of the latter half of pregnancy. 
Therefore, to avoid measurement error in the exposure, only non-preeclamptic pregnancies 
with a minimum length of 20 weeks’ gestation were considered as the non-exposed group. 
The CPRD Pregnancy Register and HES Maternity File were used to identify women who had 
a completed pregnancy record.  
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Identifying a completed pregnancy 
For our study, records from the CPRD pregnancy register were retained if they were 
considered ‘complete’ (>20 weeks’ gestation), occurred between 1 January 1997 and 31 
December 2016 (study period), and were between 11 to 49 years old (inclusive) at each 
estimated pregnancy end date (Figure 1 for details). Linked records from the HES maternity 
file within the study period and age eligibility range were retained if they related to a 
completed pregnancy event in which the recorded gestational age at delivery, or the 
inferred gestational age was at least 20 weeks. See supplementary methods for details.  
 
Records of completed pregnancies from the CPRD pregnancy register and HES maternity file 
were then merged into a final ‘dataset of completed pregnancies’. Records from the same 
participant that overlapped and had a combined length of less than 385 days (55 weeks) 
were analyzed as the same pregnancy. Otherwise, they were treated as separate 
pregnancies. For HES records, pregnancy end dates were estimated using the episode start 
date and a variable containing the number of days between episode start and delivery. In 
instances without a delivery record, the latest episode end date for that pregnancy was 
considered the pregna cy end date. Where multiple records for the same pregnancy were 
identified, the duplicate with the latest end date was retained; where both CPRD and HES 
data from the same pregnancy were retained, HES end dates were considered more 
reliable. Figure 1 outlines the data linkage process between primary and secondary care 
pregnancy datasets. Supplementary methods and Figure S1 outlines further handling of 
duplicate entries.  
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Exposure 
Following identification of eligible completed pregnancy records, each pregnancy was then 
defined as either preeclamptic or non-preeclamptic using CPRD and HES records. A record of 
preeclampsia was defined according to the presence of a pre-specified list of Read or ICD10 
Codes relating to preeclampsia diagnosis (see Table S1). If a preeclampsia code was 
recorded within 20 weeks either side of a pregnancy end date, this pregnancy was labelled 
as preeclamptic. Preterm preeclampsia was a preeclamptic pregnancy in combination with a 
pregnancy record that ended prior to 37 weeks’ gestation and women with term 
preeclampsia were excluded from this analysis. Preterm pree lampsia with delivery before 
37 weeks’ gestation commonly represents a more severe and complicated form of 
preeclampsia than preeclampsia occurring at term. Furthermore, preterm preeclampsia has 
been shown to have a more significant adverse effect on cardiovascular function six months 
postpartum.16 As a result both term and preterm preeclampsia were considered in the 
analysis.  
 
In analyses with hypertensive disorders of pregnancy (HDP) as the exposure, the same 
approach of matching to pregnancy records was taken. The International Society for the 
Study of Hypertensio  in Pregnancy (ISSHP) have recently redefined preeclampsia, and 
proteinuria is now not mandatory for a diagnosis of preeclampsia. Rather, this is diagnosed 
by the presence of de novo hypertension after 20 weeks’ gestation accompanied by 
proteinuria and/or evidence of maternal acute kidney injury, liver dysfunction, neurological 
features, hemolysis or thrombocytopenia, and/or fetal growth restriction.1 In this study, a 
record of HDP was based on any one of the Read and/or ICD10 codes listed in Table S1 
relating to a diagnosis in primary and/or secondary care of preeclampsia, gestational 
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hypertension, superimposed preeclampsia, or pre-existing hypertension during pregnancy. 
When there was more than one pregnancy the woman remained unexposed unless she had 
a preeclamptic event, at which point she became exposed and remained exposed for the 
rest of follow up (even if in subsequent pregnancies she did not suffer from preeclampsia). 
Time to event restarted after each successive pregnancy. 
 
Endpoints 
The 12 cardiovascular disorders selected as outcomes were as follows: ischaemic stroke, 
intracerebral haemorrhage, subarachnoid haemorrhage, stroke not otherwise specified 
(NOS), myocardial infarction, stable angina, unstable angina, coronary heart disease NOS, 
peripheral arterial disease, abdominal aortic aneurysm, trial fibrillation, and heart failure. 
These phenotypes were defined using all inferred or diagnosed cases of previously validated 
and replicable CALIBER EHR-algorithms (for details see 
https://www.caliberresearch.org/portal/).9, 12, 17-19 In addition, for this analysis we created 
the end-point of cardiovascular death using ONS underlying cause of death data as recorded 
on death certificates. Any record of cause coded within the ICD10 ‘I’ branch or the ICD9 39 
to 45 branches was considered a cardiovascular death. Composite outcomes were created 
according to the following groupings: all stroke (ischaemic stroke, intracerebral 
haemorrhage, subarachnoid haemorrhage, stroke NOS), all peripheral disease (peripheral 
arterial disease, abdominal aortic aneurysm), cardiac atherosclerotic (myocardial infarction, 
stable angina, coronary heart disease NOS), other cardiovascular (heart failure, atrial 
fibrillation), and all cardiovascular (all 12 cardiovascular outcomes plus any record of 
cardiovascular mortality). Following peer review, chronic hypertension was added as an 
additional outcome. If a woman’s first incident event in any of the single or composite 
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endpoint analyses occurred within six weeks of a pregnancy end date this was excluded 
from the analysis. We judged these to be acute cardiovascular events related to pregnancy 
and of different aetiology to the ones of interest in this analysis. In each individual analysis, 
pregnancies occurring after any cardiovascular event of the relevant type were excluded. 
  
Linked participant records were followed from the start of their first completed pregnancy 
record until the study end date (31 December 2016), ONS registered death, or initial 
presentation of the cardiovascular disorder under analysis, whichever was earliest.   
 
Statistical methods  
Associations with each cardiovascular end-point were modelled independently and women 
could contribute to more than one incident event. Hazard ratios (HRs) were calculated using 
disease specific cox-proportional regressions with preeclampsia, HDP, or preterm 
preeclampsia as a time-varying exposure and time since end of each pregnancy to 
event/censoring as the timescale. The survival 2.41-3 package in R was used to calculate 
hazard ratios. The proportional hazards assumption was verified using statistical (global and 
per variable) and graphical diagnostics based on Schoenfeld residuals. The results are 
presented as HR with 95% confidence intervals (CIs). The main adjusted model controlled 
for maternal ethnicity,20 maternal pre-pregnancy hypertension (prior to first pregnancy), 
maternal pre-pregnancy diabetes (prior to first pregnancy), index of multiple deprivation 
(IMD),21 pregnancy number, and maternal age. The last two variables were included as time-
varying confounders. To address the issue of correlation between pregnancies within a 
single woman we calculated robust standard errors for the adjusted analyses using a cluster 
term with patient ID within the Cox model.  
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In the Cox models, the exposures (preeclampsia, preterm preeclampsia, and HDP) were 
treated as time-varying, in which women who had more than one pregnancy during follow-
up could contribute time to both unexposed and exposed groups, prior to the occurrence of 
a cardiovascular event or censoring (see Figure S2 for schematic example of time-varying 
models). Once a woman had a record of preeclampsia or HDP she remained in that group 
for the rest of her follow-up, such that only two categories existed: no preeclampsia/HDP, or 
one or more preeclampsia/HDP. For descriptive analyses, phenotype validation, and 
cumulative incidence analyses only the woman’s first recorded pregnancy and relevant 
preeclampsia exposure were considered, and any later pregnancy events were ignored. 
 
The preeclampsia exposure phenotype was validated by comparison to a published 
systematic review of risk factors for preeclampsia.18 Study design attributes of the present 
study and the comparator study can be found in Table S2 and Figure S3. 
 
Baseline variables and covariates 
All baseline variables were compiled using the most recent measurement closest to 16 
weeks’ gestation of a woman’s first recorded completed pregnancy. For body mass index 
(BMI), records prior to five years before first pregnancy start were excluded and for pre-
pregnancy blood pressure readings used in phenotype validation, those prior to one year 
before first recorded pregnancy were also discarded. For full details on construction of all 
baseline variables see supplementary methods. Maternal age and pregnancy number (1 as 
first recorded completed pregnancy within study period) were included in models as time-
varying covariates that were re-assessed with each pregnancy event. 
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An additional nested model was run to investigate the potential mediating associations of 
post-pregnancy hypertension on cardiovascular risk. Women with pre-pregnancy (inferred 
or diagnosed) hypertension (prior to first recorded pregnancy) were excluded from this 
model and an additional time-varying covariate for post-pregnancy hypertension diagnosis 
was added to the main adjusted cox-model.  We quantified the percentage of excess risk (on 
an additive scale) explained by post-pregnancy hypertension by comparing this nested 
model to our main model using the formula ((HRModel-1-HRModel2)/(HRModel-1))x100. To 
evaluate the impact of pre-pregnancy BMI we ran a third nested model in a sub-sample with 
available data. 
 
To increase comparability of our preeclampsia phenotype against the report of Bartsch et 
al.,22 we calculated the unadjusted relative risks and 95% CIs using the R package epiR v0.9-
79. Cumulative incidence comparisons were calculated using the etmCIF function in the R 
package etm v0.6-2, which uses a survival model in which time from end of first pregnancy 
to first appearance of any of our 12 cardiovascular events or cardiovascular death was used 
as the time-scale.  All statistical and graphical analyses were carried out in R version 3.4.3.  
 
Data access and analysis 
The study was approved by the Independent Scientific Advisory Committee for the 
Medicines and Healthcare Products Regulatory Agency (protocol number 16_280R). The 
funders had no role in the study design, data collection, data analysis, data interpretation, 
or writing of the report. The first author had full access to all the data in the study and all 
authors had final responsibility for the decision to submit the manuscript for publication. 
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RESULTS 
Participants 
The study cohort included 1,899,150 unique pregnancies from 1,303,365 women (Figure 1). 
A total of 434,955 (33.37%) women had more than one pregnancy during the follow-up 
period. A total of 31,478 (2.42%) women had 33,344 preeclamptic pregnancies, of which 
25,554 (76.64%) occurred in the first pregnancy, 5,811 (17.43%) in the second, and 1,979 
(5.93%) in the third or later pregnancy.  
 
Our EHR-derived preeclampsia phenotype reproduced a very similar pattern of association 
between 10 pre-pregnancy risk factors and preeclampsia, to those reported in a recently 
published systematic review (Figure S3).23 We also reproduced the well-known association 
between pre-pregnancy blood pressure levels and preeclampsia risk (Figure 2), extending 
this to show a log-linear relationship across the full spectrum of measurements, without 
evidence of a threshold effect.  
 
Distribution of maternal characteristics by preeclampsia status for each participant’s first 
recorded completed pregnancy are shown in Table 1. As expected, women who had 
preeclampsia were more likely to be nulliparous, diabetic, hypertensive, and overweight or 
obese, and less likely to be smokers (all P-values <0.001). Pregnancies affected by 
preeclampsia were more likely to be delivered preterm (compared to those without) and 
had a lower mean infant birthweight (both P-values <2.2x10-16).  
 
Outcome data 
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After a median follow-up of 9.25 (interquartile range=5.53-13.78) years, 18,624 first 
incident, and 21,798 total cardiovascular events of any type were recorded. In our cohort 
12,129 (65.12%) of these 18,624 first events occurred in women below 40 (age at event 
density distribution is reported for any cardiovascular outcome in Figure S4)). Although in 
absolute numbers women with preeclampsia had fewer cardiovascular events than those 
without preeclampsia (861 v 17,763), in relative terms, the proportion in the preeclamptic 
group was approximately double that in the non-preeclamptic group (2.77% v 1.40%).  
 
Hazard ratios from multivariable time-dependent Cox models describing the association 
between preeclampsia and each cardiovascular disorder are shown in the upper panel of 
Figure 3. Women exposed to preeclampsia had a higher hazard ratio than those without a 
preeclamptic pregnancy, for all 12 cardiovascular events, cardiovascular mortality and 
chronic hypertension, except for intracerebral haemorrhage and abdominal aortic 
aneurysm. Overall, having at least one preeclamptic event increased a woman’s hazard of 
first incidence of any subsequent cardiovascular event by 1.69 (95% CI=1.57-1.81), and this 
strength of association was broadly consistent across major categories and single end-
points. When the same analyses were repeated with HDP as the exposure of interest, a very 
similar pattern of association was observed, whilst with preterm preeclampsia the point 
estimates were generally higher but showed greater uncertainty (mid and bottom panel, 
Figure 3). Across all categories of hypertensive disorders of pregnancy, we observed an 
elevated adjusted hazard for chronic hypertension, the highest being in those pregnancies 
affected by preterm preeclampsia (HR 5.65 (95% CI 5.10-6.26)). Adjusted and unadjusted 
results (HR, 95% CIs and P values) are shown in Table S3, S4 and S5. 
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Adjustment for diagnosis of hypertension following end of pregnancy and preceding a first 
cardiovascular event, attenuated the associations between preeclampsia and cardiovascular 
events. Adjusted HR for all stroke was 1.68 (1.30-2.18), cardiac atherosclerotic was 1.45 
(1.32-1.59), other cardiovascular disease was 1.43 (1.15-1.76), all peripheral disease was 
1.60 (1.12-2.29), and for all cardiovascular events combined was 1.45 (1.34-1.57). Similar 
results were observed for HDP, and again tended to be higher but also attenuated with 
preterm preeclampsia (see Table S6).  After we added post-pregnancy hypertension into the 
originally adjusted model to estimate its potentially mediating effect, we observed a 34.78% 
reduction in the point estimate of the HR for any CVD event. Of the 861 women who had a 
preeclampsia event prior to their first incident cardiovascular event, only 184 (21.37%) also 
had a pre-existing diagnosis of hypertension. 
 
In a sub-sample of participants (N=375,009) with available data on pre-pregnancy BMI in 
addition to all previously used confounders, HRs showed the same increase in risk but were 
attenuated between 15.94% and 66.67% for all composite outcomes and exposures. Given 
the significant reduction in number of events there was also a substantial loss in precision of 
these estimates (see Table S7 for comparisons).  
 
Figure 4 shows the cumulative incidence of any cardiovascular event according to 
preeclampsia status, using time since first pregnancy as the timescale. Difference in 
cumulative incidence was evident as early as one year after the index pregnancy. By two 
years after first pregnancy, the cumulative incidence of any cardiovascular event in women 
with preeclampsia was double that of women without preeclampsia.   
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DISCUSSION 
This is the largest contemporaneous population-based cohort study that systematically 
considers the association between hypertensive disorders of pregnancy and the incidence of 
12 common cardiovascular phenotypes. We have shown that HDP, preeclampsia and 
preterm preeclampsia have a largely similar pattern of increased risk for all cardiovascular 
disorders. The impact is evident as early as one year after the index pregnancy.    
 
In line with previous studies we found that preeclampsia and HDP almost double the risk of 
a subsequent cardiovascular event and preterm preeclampsia leads to an even larger 
inflated risk.4-8, 10, 11, 23-28 We report for the first time the association between preeclampsia, 
HDP, and preterm preeclampsia with sub-types of stroke, peripheral vascular disease, and 
atrial fibrillation, and we improve the resolution for others (heart failure, stable angina), in 
which prior evidence was limited.4-8, 10, 11, 23-28 Secondly, the magnitude of the associations of 
preeclampsia with specific cardiovascular disorders was homogenous, with a similar pattern 
observed for HDP and a slightly further raised risk for preterm preeclampsia. Thirdly, the 
differences in cumulative incidence for cardiovascular events appear as early as one year 
post-partum.  These novel findings suggest that a diagnosis of HDP (which is more common 
than preeclampsia; 7.41% of women had at least one diagnosis of HDP in our study versus 
2.42% for preeclampsia only) can be used as an “opportunistic screening tool” to identify 
women at higher risk of cardiovascular events. 
 
The fact that the magnitude of the association of HDP with all 12 cardiovascular disorders 
was homogenous favours the use of HDP as a screening tool for total cardiovascular risk (i.e. 
all 12 cardiovascular disorders). This is an expansion of the available recommendations by 
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clinical guidelines, such as those from the American Heart Association (AHA)29 and the 
European Society of Cardiology30 that concentrate on preeclampsia as the screening tool, 
and coronary heart disease and stroke as the outcomes to prevent. Clinical guidelines, such 
as those produced by the AHA, have made excellent steps towards early post-pregnancy 
detection and control of cardiovascular risk factors such as hypertension.31, 32 In our UK 
cohort, one in five of the 861 preeclamptic women who suffered a cardiovascular event had 
been diagnosed with hypertension, and this, together with early separation in the survival 
curves (1-year post-partum), highlights the need for active screening and control of 
cardiovascular risk factors in this selected group.   
 
Our study has multiple strengths that secure the validity of our findings. Firstly, the 
incidence of preeclampsia in our cohort was 2.42%, not dissimilar to previous estimates.33 
Secondly, unlike most previous studies,3, 6-8, 10, 25-28 we conducted an extensive validation of 
our EHR preeclampsia phenotype beyond simple comparisons of baseline risk-factors. 
Thirdly, the 12 cardiovascular phenotypes used as outcomes have all been previously 
validated and shown to be highly reproducible.9, 12, 17-19  
 
The quality and comprehensiveness of the EHR resources used for our study allowed us to 
include time-dependent exposures and covariates in our Cox models, which is preferable to 
baseline only models. However, it is important to highlight some limitations. Firstly, the 
substantial level of missingness in the EHR records of pre-pregnancy BMI and smoking 
(>60%) limited the validity of using multiple imputation and therefore precluded their 
inclusion in the final models. Taken together with the observational nature of our analysis 
this introduces the potential for residual confounding to be a partial, or total, explanation to 
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our results. However, adjustment for pre-pregnancy BMI (in a sub-sample) did not 
substantially change our conclusions. Other limitations include potential selection bias and 
inaccuracy of data collection. Although it is theoretically possible to have some degree of 
misclassification in the exposure (i.e. preeclampsia), we judged that inaccuracies in coding 
are unlikely to be related to hypertensive disorders. As a consequence the impact on 
exposure misclassification is just random error which is largely overturned by large dataset. 
It is possible that women who had a previous pregnancy prior to the start of the study 
period (either hypertensive or normotensive) might be mislabelled if their first pregnancy is 
not captured. However, we consider that it is likely that this has happened on a small scale 
and to a similar degree for previous hypertensive and normotensive pregnancies and 
therefore is not likely to have a substantial impact on our findings. The potential impact of 
non-CVD mortality as a competing risk on CVD events was assessed but had no impact on our results 
(Table S8). In the present study we did not evaluate whether addition of preeclampsia or 
HDP history has an incremental benefit over established risk-algorithms for cardiovascular 
disease in middle age (e.g. QRISK, Framingham).34  
 
The precise mechanisms that explain the association between preeclampsia or HDP and 
cardiovas ular disorders remain a matter of debate. A potential explanation is that shared 
risk factors between preeclampsia and cardiovascular disorders, such as hypertension and 
obesity, are at least partially responsible. Our findings are in favour of this hypothesis. 
Firstly, adjustment for hypertension that occurs post-pregnancy but prior to the 
cardiovascular event reduced the hazard ratios. This is in partial agreement with the findings 
by Canoy et al10 who also identified hypertension between pregnancy and coronary heart 
disease or stroke as an important modifying factor in risk.  Secondly, high blood pressure is a 
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common risk factor for HDP and preeclampsia and has homogenous associations with the 
12 cardiovascular disorders we evaluated,9 which could explain the similar pattern of 
homogenous associations that preeclampsia and HDP had on cardiovascular disorders 
evaluated. Thirdly, the almost immediate, post-pregnancy separation in the cumulative 
incidence on cardiovascular events by preeclampsia status (Figure 4) suggests it is more 
likely to be pre-pregnancy risk factors such as hypertension rather than only a de-novo 
insult created by preeclampsia that explains these observations.  
 
Further work is required to estimate how many cardiovascular events could be avoided by 
implementing interventions such as active high blood pressure detection and control in 
women that had experienced HDP. The large-sc le EHR resource we have created also 
serves as a unique opportunity to systematically test the theory that pregnancy can be 
conceived of as a “stress-test” for future development of chronic disease.5 
 
In conclusion, we have showed that preeclampsia, preterm preeclampsia, and HDP have a 
similar pattern of increased risk for the 12 most common cardiovascular disorders observed 
in women in Britain, highlighting the opportunity to use HDP as a naturally occurring 
screening tool to detect women at high risk of cardiovascular events. 
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Figure 1: Flow diagram outlining construction of final pregnancy and preeclampsia cohort 
using CPRD and HES datasets. *strategy for dealing with duplicate entries is outlined in 
supplementary methods 
 
Figure 2: Odds ratios (OR) for risk of preeclampsia from a subset of first recorded 
pregnancies with available blood pressure (BP) readings. BP taken up to 1 year prior to 
pregnancy start and within 16 weeks of gestation. A) Systolic blood pressure (SBP) and odds 
of preeclampsia in each consecutive group compared to lowest group (<95), B)  Diastolic 
blood pressure (DBP) and odds of preeclampsia in each consecutive group compared to 
lowest group (DBP<55). Red dotted line indicates a weighted regression cubic spline with 
95% CIs. 
 
Figure 3: Forest plot of adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for 
12 cardiovascular outcomes, relevant composites, and chronic hypertension, given exposure 
to A) Preeclampsia; B) Hypertensive disorders of pregnancy; C) Preeclampsia with preterm 
birth. All HRs were computed using a Cox-proportional hazards model with time-dependent 
exposure and adjusted for associations of maternal ethnicity, maternal age, pre-pregnancy 
diabetes, pre-pregnancy hypertension, index of multiple deprivation, and a cluster term to 
account for correlation within patients. Events are numbers of events in the exposure group 
only. 
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Figure 4: Cumulative incidence (with 95% confidence interval) of first cardiovascular event 
by preeclampsia status by years since end of first recorded pregnancy Numbers at risk in 
each group for each x-axis tick mark are listed by colour of exposure. Graph was only plotted 
up until the point that the numbers at risk in the control group were at least 10% of the 
maximum control group size. 
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Table 1. Summary of maternal demographic, first recorded pre-pregnancy, and delivery characteristics. Missingness recorded where present. 
Maternal characteristic All 
(1,303,365) 
No PE 
(N=1,277,811) 
PE 
(N=25,554) 
Maternal age at delivery (years), mean (SD) 28.48 (6.15) 28.47 (6.15) 28.61 (6.29) 
Ethnicity, n (%)    
Asian 69073 (5.30) 67849 (5.31) 1224 (4.79) 
Black 48427 (3.72) 47124 (3.69) 1303 (5.10) 
Other 63283 (4.86) 62338 (4.88) 945 (3.70) 
Unknown 80233 (6.16) 79233 (6.20) 1000 (3.91) 
White 1042349 (79.97) 1021267 (79.92) 21082 (82.50) 
Practice IMD 2015, n (%)    
Quintile 1 (least deprived) 196375 (15.07) 192832 (15.09) 3543 (13.86) 
Quintile 5 (most deprived) 320220 (24.57) 313612 (24.54) 6608 (25.86) 
At first recorded pregnancy booking    
Diabetes, n (%) 3378 (0.26) 3020 (0.24) 358 (1.40) 
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Hypertension, n (%) 29144 (2.24) 27027 (2.12) 2117 (8.28) 
Nulliparity, n (% of known)  294996 (64.66)  285189 (64.43)  9807 (72.06)  
Missing (%) 847146 (65.00) 835202 (65.34) 11944 (46.74) 
Pre-pregnancy BMI (kg/m2) (% of known)    
Underweight (<18.5) 18045 (4.77) 17720 (4.84) 325 (2.80) 
Healthy (18.5-24.9) 226246 (59.85) 220853 (60.28) 5393 (46.46) 
Overweight (25-29.9) 83692 (22.14) 80536 (21.98) 3156 (27.19) 
Obese (30-39.9) 44466 (11.76) 42107 (11.49) 2359 (20.32) 
Severely obese (>40) 5553 (1.47) 5177 (1.41) 376 (3.24) 
Missing (%) 925363 (71.00) 911418 (71.00) 13945 (54.57) 
Ever smoker, n (% of known) 199254 (39.18)  193893 (39.31)  5361 (34.87)  
Missing (%) 794754 (60.98)] 784575 (61.40) 10179 (39.83) 
Multi-fetal pregnancy, n (% of known)  30471 (2.86)  29261 (2.80)  1210 (6.00)  
Missing (%) 227809 (17.48) 222490 (17.41) 5319 (20.81) 
Gestational diabetes, n (%) 17199 (1.32) 16344 (1.28) 855 (3.35) 
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At delivery    
Gestational age at birth (weeks), mean (SD) 39.15 (2.53) 39.18 (2.5) 37.81 (3.14) 
Preterm birth (<37 weeks), n (%) 53652 (4.12) 48500 (3.80) 5152 (20.16) 
Infant birthweight* (grams), mean (SD)  3339 (590)  3348 (580)  2899.44 (845)  
Missing (%) 311624 (23.91) 305661(23.92) 5963 (23.33) 
*For multi-fetal pregnancies this refers to the last delivered infant 
Dis
cla
im
er:
 Th
e m
an
us
cri
pt 
an
d
 
 
its
 co
nte
nts
 ar
e c
on
fid
en
tia
l,
 
 
 
 
int
en
de
d f
or 
jou
rna
l re
vie
w
 
 
pu
rpo
se
s o
nly
, a
nd
 no
t to
 be
 
 
 
 
 
 
 
 
 
 
 
 
fur
the
r d
isc
los
ed
.
 Dis
cla
im
er:
 Th
e m
an
us
cri
pt 
an
d i
ts 
co
nte
nts
 ar
e
co
nfi
de
nti
al,
 in
ten
de
d f
or 
jou
rna
l re
vie
w p
urp
ose
s
 
 
 
 
 
 
 
 
 
 
 
on
ly,
 an
d n
ot 
to 
be
 fu
rth
er 
dis
clo
se
d.
 Dis
cla
im
er:
 Th
e m
an
us
cri
pt 
an
d i
ts 
co
nte
nts
 ar
e
co
nfi
de
nti
al,
 in
ten
de
d f
or 
jou
rna
l re
vie
w p
urp
ose
s
 
 
 
 
 
 
 
 
 
 
 
on
ly,
 an
d n
ot 
to 
be
 fu
rth
er 
dis
clo
se
d.
 Dis
cla
im
er:
 Th
e m
an
us
cri
pt 
an
d i
ts 
co
nte
nts
 ar
e
co
nfi
de
nti
al,
 in
ten
de
d f
or 
jou
rna
l re
vie
w p
urp
ose
s
 
 
 
 
 
 
 
 
 
 
 
on
ly,
 an
d n
ot 
to 
be
 fu
rth
er 
dis
clo
se
d.
 Dis
cla
im
er:
 Th
e m
an
us
cri
pt 
an
d i
ts 
co
nte
nts
 ar
e
co
nfi
de
nti
al,
 in
ten
de
d f
or 
jou
rna
l re
vie
w p
urp
ose
s
 
 
 
 
 
 
 
 
 
 
 
on
ly,
 an
d n
ot 
to 
be
 fu
rth
er 
dis
clo
se
d.
 Dis
cla
im
er:
 Th
e m
an
us
cri
pt 
an
d i
ts 
co
nte
nts
 ar
e
co
nfi
de
nti
al,
 in
ten
de
d f
or 
jou
rna
l re
vie
w p
urp
ose
s
 
 
 
 
 
 
 
 
 
 
 
on
ly,
 an
d n
ot 
to 
be
 fu
rth
er 
dis
clo
se
d.
